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Abstract
Overdiagnosis is diagnosis of cancers that would not present
within the life of the patient and is one of the downsides of
screening. This applies to low-grade ductal carcinoma in situ and
some small grade 1 invasive cancers. Radiologists are responsible
for cancer diagnosis, but at the time of diagnosis they cannot
determine whether a particular low-grade diagnosis is one to which
the definition of overdiagnosis applies. Overdiagnosis is likely to be
driven by technological developments, including digital
mammography, computer-aided detection and improved biopsy
techniques. It is also driven by the patient’s fear that cancer will be
missed and the doctor’s fear of litigation. It is therefore an issue of
importance for radiologists, presenting them with difficult fine-
tuned decisions in every assessment clinic that are ultimately
counted later by those who evaluate their screening.
Introduction
Many of the previous entries in this review series have come
from statisticians and epidemiologists who evaluate screen-
ing programmes and guide national policies for the health
care of populations. Their calculations take into account the
benefits for health and mortality, adverse consequences,
cost-effectiveness and opportunity costs of obtaining
evidence from trials and service screening [1]. They largely
use data from events in the past to make forward decisions.
Likewise, many of the pathological data are obtained by
observing the different pathological entities in longitudinal
follow up of case material stored many years ago and linked
with outcomes. By contrast, radiologists, with the patient and
the clinical teams, make current decisions for individuals.
Overdiagnosis is the result of detecting cancers that would
not present in the patient’s life without screening.
Radiologists consider issues of overdiagnosis but they
seldom use this particular term. Considerable radiological
effort has been applied to reducing false-positive recalls,
which result in unnecessary surgery for benign disease.
Some of this literature is relevant to the present issue of
overdiagnosis, but in general when the radiologist finds a
lesion labelled cancer by a pathologist, they and the patient
regard this as a desirable event and the patient feels
gratitude for a beneficial medical service.
This situation is not unique to screening. In the current
international political debate on pensions, if individuals could
foresee their year of death and predict future fiscal
performance then they would make good decisions on
pension investment and age of retirement. This example has
an individual and a population dimension, because current
demographic changes were not foreseen when earlier
policies were laid down. To use an example from a
symptomatic clinical setting, a patient presenting with chest
symptoms and an area of shadowing on a chest radiograph
will wish to take an antibiotic for pneumonia, although the
diagnosis is not conclusive, the disease may be of viral origin
and many bacterial pneumonias resolve without treatment.
The physician knows that this will avert the small possibility of
death from pneumococcal pneumonia, a formerly life-
threatening disease that is now treatable.
Small cancer nonspecific signs
Radiological education for breast screening concentrates on
the diagnosis of invasive cancers at small size when the
tumour is fully treatable [2], because this is the situation in
which screening has an impact on mortality for some women.
As the point of diagnosis is moved ever earlier to smaller
tumours, with radiological signs that tend to become less
specific, more queries will concern benign and borderline
lesions or lesions that turn out to be low-grade in situ or
invasive tumours [3]. These are the lesions of the type found
by chance in the breasts of women who die from other
causes who are examined in the post mortem room [4].
Detection of these lesions while the patient is still alive results
in overdiagnosis, which wastes resources and places
patients at risk for overtreatment. These nonspecific signs fall
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broadly into two groups: small anonymous masses, in which
the suspicion is small invasive cancer; and calcifications,
which are more commonly associated with carcinoma in situ.
This statement would justify a policy of greater vigilance for
small masses than for calcifications. The distinction is not
complete, however. There is good evidence that calcification
may be associated with invasive tumours of aggressive type
[5]; that a high proportion of high-grade ductal carcinoma in
situ (DCIS) cases will progress to high-grade invasive
cancers if they are left untreated [6]; that screening units with
high DCIS detection rates also have high rates of detection
of small invasive cancers [7]; and that assessed patients who
later develop cancer at the assessed site frequently exhibited
calcifications that with present policies would have been
biopsied [8].
Developing technology
Since the original trials of breast screening conducted in the
1980s, there has been steady improvement in the associated
technology. Development of screen-film technology, now to
become superseded by digital mammography, has improved
the detection of small cancers [9], both small masses and
calcifications. This now has the potential to be enhanced by
computer-aided detection [10,11]. Biopsy techniques have
evolved with great sophistication, allowing tiny foci of
nonspecific calcification to be sampled with great accuracy
[12]. Lesions can be characterized further using contrast-
enhanced breast magnetic resonance imaging (MRI), which
has great sensitivity for small invasive cancers in dense
breasts [13]. MRI-guided biopsies are now showing that
DCIS can also be detected at small size in dense breasts by
contrast-enhanced MRI [14].
The availability of the techniques does not mandate their use,
but there is a steady drift toward subjecting more and smaller
lesions to biopsy, particularly because this can now be done
percutaneously rather than by open surgical biopsy. A policy
of aggressively biopsying calcification increases the rate of
detection of DCISs, some of which will be of high grade with
or without microinvasion or even of small high-grade invasive
cancers. This is useful diagnostic activity. Less useful is the
diagnosis of atypical hyperplasia and lobular carcinoma in
situ, for which the best treatment is not well understood [15].
Excision biopsy is commonly carried out for such lesions in
view of the possibility of progression to invasive cancer or the
association with DCIS, and this may well constitute
‘overtreatment’.
Informed consent
Women’s understanding of the benefits and shortcomings of
breast screening is imperfect [16]. Radiologists may be
involved in writing the leaflets that inform women and
advertisements that promote participation in screening.
However, they are much more likely to be involved in one-to-
one verbal communications with individual women when they
are informed of their mammograph findings and of the
diagnostic and treatment decisions that ensue. They are likely
to discuss the potential benefits and pitfalls of screening and
the possibility that a biopsy procedure will progress to
extensive surgery, depending on the subsequent pathological
findings. Although they have a duty to be honest, it is unlikely
that they will discuss the possibility of finding and treating a
cancer that would not have presented in life, because they
cannot prospectively distinguish such a case from one that
does progress and requires treatment.
Preferences of doctor and patient
Both patients and the doctors who advise them have a range
of attitudes to risk that are intrinsic to their personalities.
Decisions will be a composite of the interaction of the two
personalities. A doctor who is heavily risk averse is likely to
advise a patient to proceed to biopsy and treatment of any
suspect lesion, and many patients take the view that they
wish no stone to be left unturned to ensure that they do not
have cancer. The policies of a screening unit will represent
the consensus of the attitudes of the participant radiologists,
backed by procedures for policy made at national level. The
UK National Health Service Breast Screening Programme
has a policy document for assessment procedures [17].
Although a document of this type is designed to provide
guidance, it can become the benchmark by which individual
practitioners and their decisions are judged. This promotes
more intensive biopsying of radiologically indeterminate
lesions in a drive to improve cancer detection but at the cost
of overdiagnosis.
Litigation
Screening carries with it the implicit problem that some
cancers will not be diagnosed by screening, and it has been
shown that in any screening programme a small proportion of
these cancers will be visible on hindsight [18]. Inevitably, this
results in dissatisfaction because patients feel that the
screening programme, and more specifically the radiologist,
has let them down, and should be called to account. Some of
these women will pursue their claim through the courts. This
environment creates a culture in which no stone is left
unturned [19]. The doctor fears the accusation of missing a
cancer and so will err on the side of caution and risk
overdiagnosis. Few patients will complain that too much was
done, but one of the authors of this review (RW) recently had
litigation pending (finally dropped before going to court) on
account of calcification not biopsied but later shown to be
benign in the field of an emergent breast cancer.
Concurrently, another patient made a major complaint about
surgical ‘mutilation’ resulting from removal of an area of
atypical ductal hyperplasia. Complaints and litigation are a
minefield in which one realizes that individual patients have
widely differing attitudes to priorities for their care.
The effect of age
Thus far the discussion has referred to population screening
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mammographic screening (say 45–75 years). Age and familial
risk level will affect the incidence of cancer (invasive and
noninvasive) in the screened population. Costs and benefits
will differ, and so may the probability of overdiagnosis. When
screening women who are younger than 45 years, some of
the points made above will not apply. The detection of DCIS,
whatever the grade, may be expected to be worthwhile
because there are many more potential years of life for these
lesions to progress from in situ to invasive disease. Similarly,
low-grade invasive cancer may well have time to affect the
woman’s health. Cancers diagnosed in women under 45
years old have a greater probability of being of high grade
than in older women [2]. On the other hand, the background
incidence of cancer is lower, so proportionally the downsides
of screening, including overdiagnosis, are of greater magnitude.
For older women (those older than 75 years), both the
incidence and the detection of cancer are high, so the
probability of a small tubular carcinoma or low-grade DCIS
being found that would never present clinically is greater.
Other fatal diseases become more common at this age, and it
is these intercurrent diseases that increase the risk for
overdiagnosis, because more women will die from other
causes before their screen-detected cancer would become a
problem [20].
High-risk groups
For high-risk groups the calculations will be different. For
women with germline mutations in breast cancer suscepti-
bility genes, particularly BRCA, the cancers are likely to be of
high grade, and the discovery of DCIS is infrequent [21].
Overdiagnosis is unlikely to occur, and all suspect findings
should be pursued to full diagnosis and treatment. This would
be the wish of such high-risk patients, but it is also logical,
irrespective of age. The biology of cancers in women who
received mantle radiotherapy for lymphoma in adolescence
may differ from those related to germline mutations, but again
the incidence of cancer in this group will justify a high level of
caution with any lesion. The psychological reaction of women
with higher levels of risk has not been fully evaluated and may
not necessarily be the same as that of women who are at
standard risk. A recent systematic review identified this as a
research priority [22].
Overdiagnosis and treatment decisions
Radiologists in screening programmes provide the role of
diagnostic physicians working with surgeons and oncologists
in the multidisciplinary team. They have a duty in view of their
understanding of cancer to use their influence to bring sanity
to treatment decisions for minimal cancers. In such cases,
these teams must consider whether the treatment options
should be used conservatively: axillary clearance would be
overtreatment for a small tubular carcinoma; mastectomy
would be an excessive surgical choice for a small area of low-
grade DCIS; and radiotherapy, which may potentially affect
cardiac or pulmonary performance, may not be needed for
small low-grade invasive tumours or low-grade DCIS. These
women need a balanced approach to their treatment, which
takes into account the concept that screening is a procedure
driven by health policy and is different from disease of
symptomatic presentation. Patients may need protection from
their doctors, and fully informed consent is essential to the
individual woman’s understanding of her disease.
Conclusion
Radiologists are the physicians who implement the breast
screening policies proposed by public health physicians,
epidemiologists and health service managers. They are the
ones who make the overdiagnosis happen, but they do this in
ignorance of the evolution of the disease that they diagnose
in each individual woman. When the patient asks, ‘Will my
disease kill me?’ or ‘Will my disease return after treatment?’,
the radiologist can only reply with probabilities and cannot tell
the patient what will happen to them as an individual.
Overdiagnosis is therefore a difficult issue for radiologists. It
sits in the pan of a balance that has litigation and missed
cancer in the other pan, and is as much a matter of patient
wellbeing. It is therefore an issue of importance for
radiologists, presenting them with difficult fine-tuned
decisions in every assessment clinic that are ultimately
counted later by those who evaluate their screening.
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